ML 351|CAS 847163-28-4|DC Chemicals

Cas No.:	847163-28-4
Chemical Name:	ML351
Synonyms:	ML351 NEW;Capecitabine-d11;ML 351;5-(Methylamino)-2-(1-naphthalenyl)-4-oxazolecarbonitrile;CID 664510;SID 104223766;ML351;5-(Methylamino)-2-(1-naphthalenyl)-4-oxazolecarbonitrile (ACI);5-(Methylamino)-2-(naphthalen-1-yl)oxazole-4-carbonitrile;GLXC-04314;HMS3313H01;CS-0034899;5-(methylamino)-2-(1-naphthyl)-1,3-oxazol-4-yl cyanide;5-(methylamino)-2-(1-naphthyl)oxazole-4-carbonitrile;BDBM79800;SCHEMBL16515652;5-Methylamino-2-naphthalen-1-yl-oxazole-4-carbonitrile;NSC818701;NSC-818701;STK905505;DYXYXTDIFMDJIR-UHFFFAOYSA-N;REGID_FOR_CID_664510;ML351, >=98% (HPLC);A1-18402;cid_664510;AKOS005183681;E98741;ML-351;MFCD04183120;GTPL10263;s3387;MS-23528;5-(methylamino)-2-(1-naphthalenyl)-4-oxazolecarbonitrile;847163-28-4;MLS004813835;NCGC00070329-02;HY-111310;DA-75604;MLS000082299;5-(methylamino)-2-(naphthalen-1-yl)-1,3-oxazole-4-carbonitrile;EN300-188357;5-(methylamino)-2-naphthalen-1-yl-1,3-oxazole-4-carbonitrile;CHEMBL1548353;HMS2156P03;Z1213743771;SMR000045344;NCGC00070329-03
SMILES:	N#CC1=C(NC)OC(C2C3C(=CC=CC=3)C=CC=2)=N1
Formula:	C₁₅H₁₁N₃O
M.Wt:	249.267342805862
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.